



# **Diagnostic Value of Video-Dermatoscopy in Patients with Systemic Sclerosis and Dermatomyositis with Its Relation to Serum Vascular Endothelial Growth Factor (S.VEGF)**

**Thesis**

***Submitted For Partial Fulfillment of Master Degree  
in Dermatology, Venerology and Andrology***

**By**

***Naglaa Fathy Salama Sayed***

***M.B.B.Ch***

***Faculty of Medicine, Ain Shams University***

**Supervised by**

**Prof. Dr. Hoda Ahmed Mounib**

***Professor of Dermatology, Venereology and Andrology  
Faculty of Medicine, Ain Shams University***

**Dr. Rania Mahmoud Elhusseiny**

***Lecturer of Dermatology, Venereology and Andrology  
Faculty of Medicine, Ain Shams University***

**Ain Shams University  
Faculty of Medicine**

**2020**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قالوا

سبحانك لا علم لنا  
إلا ما علمتنا إنك أنت  
العليم العليم

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Hoda Ahmed Mounib**, Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks to **Dr. Rania Mahmoud Elhusseiny**, Lecturer of Dermatology, Venereology and Andrology, Faculty of Medicine, Ain Shams University, for her sincere efforts and fruitful encouragement.*

*I would like to express my hearty thanks to all **my family** for their support till this work was completed.*

*Last but not least my sincere thanks and appreciation to all patients participated in this study.*

***Naglaa Fathy Salama Sayed***

# List of Contents

Title	Page No.
List of Abbreviations .....	i
List of Tables .....	iii
List of Figures .....	v
Introduction.....	- 1 -
Aim of the Work .....	6
Review of Literature	
➤ Systemic Sclerosis .....	7
➤ Dermatomyositis .....	26
➤ Dermoscopy .....	44
➤ Vascular Endothelial Growth Factor .....	50
Subjects and Methods.....	53
Results.....	63
Discussion .....	93
Conclusion .....	103
Recommendations.....	104
Limitations.....	104
Summary .....	105
References.....	110
Arabic Summary.....	١

# LIST OF ABBREVIATIONS

Abb.	Full term
<i>ALT</i>	: Alanine Amino-Transferase
<i>AIF-1</i>	: Allograft Inflammatory Protein 1
<i>ACR</i>	: American College of Rheumatology
<i>ADM</i>	: Amyopathic Dermatomyositis
<i>ACE</i>	: Angiotension Converting Enzyme
<i>ACA</i>	: AnticentromerAntibody
<i>ANA</i>	: Anti-Nuclear Antibody
<i>AUC</i>	: Area under curve
<i>AST</i>	: Aspartate Amino-Transferase
<i>AZA</i>	: Azathioprine
<i>CS</i>	: Corticosteroid
<i>CK</i>	: Creatinine Kinase
<i>CMV</i>	: Cytomegalovirus
<i>DM</i>	: Dermatomyositis
<i>DcSSc</i>	: Diffuse Cutaneous Systemic Sclerosis
<i>DMARDs</i>	: Disease Modifying Anti-Rheumatic Drugs
<i>EBV</i>	: Ebstein-Barr Virus
<i>ET-1</i>	: Endothelin 1
<i>ELISA</i>	: Enzyme-Linked Immunosorbent assay
<i>EuLAR</i>	: European League Against Rheumatism
<i>ENA</i>	: Extra-Nuclear Antibody
<i>HMG B1</i>	: High Mobility Group Protein B1
<i>IIM</i>	: Idiopathic Inflammatory Myopathy
<i>IBM</i>	: Inclusion Body Myositis
<i>IFN</i>	: Interferon
<i>IL</i>	: Interleukin
<i>ILD</i>	: Interstitial Lung Disease
<i>IVIG</i>	: Inter-Venous Immunoglobulin
<i>JDM</i>	: Juvenile Dermatomyositis
<i>LDH</i>	: Lactate Dehydrogenase
<i>LcSSc</i>	: Limited Cutaneous Systemic Sclerosis
<i>MHC</i>	: Major Histocompatibility Complex
<i>MDA-5</i>	: Melanoma differentiation induced gene-5
<i>MTX</i>	: Methotrexate
<i>McTD</i>	: Mixed Connective Tissue Disease
<i>MRSS</i>	: Modified Random Skin Score

# LIST OF ABBREVIATIONS (CONT...)

Abb.	Full term
<i>MCP-1</i>	: Monocyte Chemo-attractant Protein 1
<i>MMF</i>	: Mycophenolate Mofetil
<i>MAA</i>	: Myositis Associated Auto-antibody
<i>MSA</i>	: Myositis Specific Auto-antibody
<i>NVD</i>	: Nail fold Video-Dermatoscopy
<i>NPV</i>	: Negative predictive value
<i>NS</i>	: Non-significant
<i>OD</i>	: Optical Density
<i>PDE-5</i>	: Phosphodiesterase-5
<i>PDGF</i>	: Platelet Derived Growth Factor
<i>PM</i>	: Polymyositis
<i>PPV</i>	: Positive predictive value
<i>PG</i>	: Prostaglandin
<i>PUVA</i>	: Psoralen Plus ultraviolet
<i>RP</i>	: Raynaud's Phenomenon
<i>T-reg</i>	: Regulatory T Cell
<i>RA</i>	: Rheumatoid Arthritis
<i>RTX</i>	: Rituximab
<i>SP</i>	: Scleroderma Pattern
<i>S. VEGF</i>	: Serum Vascular Endothelial Growth Factor
<i>SLE</i>	: Systemic Lupus Erythematosus
<i>SSc</i>	: Systemic Sclerosis
<i>Th</i>	: T-helper Cell
<i>TIF-<math>\gamma</math></i>	: Transcriptional intermediary factor
<i>TGF</i>	: Transforming Growth Factor
<i>TNF</i>	: Tumor Necrosis Factor
<i>UVR</i>	: Ultraviolet Radiation
<i>VD</i>	: Video-Dermatoscopy

# LIST OF TABLES

Table No.	Title	Page No.
<b>Table (1):</b>	Characteristics of limited cutaneous and diffuse cutaneous systemic sclerosis .....	9
<b>Table (2):</b>	Cutaneous manifestations of dermatomyositis.....	33
<b>Table (3):</b>	Autoantibodies in dermatomyositis.....	38
<b>Table (4):</b>	Classification of nail fold capillary patterns in SSc and DM.....	58
<b>Table (5):</b>	Comparison between age of studied patients and controls .....	65
<b>Table (6):</b>	Clinical characteristics of SSc patients .....	66
<b>Table (7):</b>	Clinical characteristics of DM patients .....	67
<b>Table (8):</b>	Nailfold capillary findings by video-dermoscopy among studied patients .....	68
<b>Table (9):</b>	Classification of NVD patterns among studied patients .....	69
<b>Table (10):</b>	NVD patterns distribution of both SSc and DM patients .....	70
<b>Table (11):</b>	Comparison between NVD pattern of LcSSc and DcSSc patients.....	71
<b>Table (12):</b>	Relations between patients' age and disease duration with NVD patterns in SSc patients.....	72
<b>Table (13):</b>	Relation between patients' age and disease duration with NVD patterns in DM patients.....	73
<b>Table (14):</b>	Relation between Finger or nail affection and NVD pattern in SSc Patients .....	74
<b>Table (15):</b>	Relation between finger or nail affection and NVD pattern in DM Patients .....	75
<b>Table (16):</b>	Relation between internal organ involvment and NVD pattern in SSc patients .....	76
<b>Table (17):</b>	Relation between internal organ involvment and NVD pattern in DM Patients.....	76
<b>Table (18):</b>	Comparison between serum VEGF in cases and controls .....	77

## LIST OF TABLES (CONT...)

Table No.	Title	Page No.
<b>Table (19):</b>	Comparison between serum level of VEGF in limited and diffuse cutaneous SSc patients.....	79
<b>Table (20):</b>	Relation between serum level of VEGF and patterns of NVD in SSc patients .....	80
<b>Table (21):</b>	Relation between serum levels of VEGF and patterns of NVD in DM patients .....	81
<b>Table (22):</b>	Relation between patients' age and disease duration with serum level of VEGF in patients with SSc .....	82
<b>Table (23):</b>	Relation between patients' age and disease duration with serum level of VEGF in patients with DM .....	84
<b>Table (24):</b>	Relation between finger or nail affection and serum VEGF level in SSc patients.....	84
<b>Table (25):</b>	Relation between finger or nail affection and serum VEGF level in DM patients .....	85
<b>Table (26):</b>	Relation between internal organ involvement and serum VEGF level in SSc patients .....	85
<b>Table (27):</b>	Relation between internal organ involvement and serum VEGF level in DM patients .....	86



# LIST OF FIGURES

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Etiopathogenesis of systemic sclerosis .....	13
<b>Figure (2):</b>	Skin fibrosis of the fingers in SSc patient .....	16
<b>Figure (3):</b>	Widespread depigmentation resembling vitiligo in SSc patients .....	17
<b>Figure (4):</b>	Diffuse cutaneous SSc patient.....	17
<b>Figure (5):</b>	Histopathology of systemic sclerosis .....	19
<b>Figure (6):</b>	A practical approach to the management of a patient with systemic sclerosis.....	24
<b>Figure (7):</b>	Proposed Mechanisms of Pathogenesis of Juvenile dermatomyositis .....	31
<b>Figure (8):</b>	Skin manifestation of dermatomyositis .....	34
<b>Figure (9):</b>	Histopathology of dermatomyositis.....	36
<b>Figure (10):</b>	An algorithm for management of a patient with dermatomyositis.....	43
<b>Figure (11):</b>	Types of dermoscopy .....	45
<b>Figure (12):</b>	Videodermatoscopy .....	46
<b>Figure (13):</b>	Nailfold dermoscopic patterns in SSc and DM .....	49
<b>Figure (14):</b>	Mechanism of action of vascular endothelial growth factor .....	52
<b>Figure (15):</b>	Percentage of studied subjects .....	63
<b>Figure (16):</b>	Classifications of studied patients.....	64
<b>Figure (17):</b>	Nailfold capillary findings by video-dermoscopy .....	68
<b>Figure (18):</b>	NVD patterns distribution among studied patients.....	69
<b>Figure (19):</b>	Comparison between NVD patterns of LcSSc and DcSSc .....	71
<b>Figure (20):</b>	Comparison between cases and controls regarding VEGF level.....	77
<b>Figure (21):</b>	ROC curve between patients & control groups regarding sVEGF level.....	78

## LIST OF FIGURES (CONT...)

Fig. No.	Title	Page No.
<b>Figure (22):</b>	Comparison between serum level of VEGF in limited and diffuse cutaneous SSc patients .....	79
<b>Figure (23):</b>	Scatter plot for correlation between age of patient and sVEGF level in patients with SSc....	82
<b>Figure (24):</b>	Scatter plot for correlation between duration of disease and sVEGF level in patients with SSc .....	83
<b>Figure (25):</b>	30 years old female with limited cutaneous SSc of 5-year duration; with serum VEGF level 800 pg/ml. ....	87
<b>Figure (26):</b>	53 years old female with diffuse cutaneous SSc of 15-year duration; with serum VEGF level 4800 pg/ml.....	88
<b>Figure (27):</b>	35 years old female with limited cutaneous SSc of 5-year duration; with serum VEGF level 1450 pg/ml.....	89
<b>Figure (28):</b>	54 years old female with DM of 14-year duration; with serum VEGF level 4300 pg/ml.....	90
<b>Figure (29):</b>	26 Years old healthy control female, with serum VEGF level 380 PG/ml.....	91
<b>Figure (30):</b>	33 Years old healthy control female, with serum VEGF level 300 PG/ml.....	92

## INTRODUCTION

Systemic sclerosis (SSc) is a systemic connective tissue disease characterized by essential vasomotor disturbances, fibrosis, subsequent atrophy of the skin, subcutaneous tissue, muscles and internal organs (e.g., alimentary tract, lungs, heart, kidney, CNS) with immunologic disturbances accompany these findings (*Park et al., 2015*).

It is due to Excessive collagen deposition which causes skin and internal organ changes. Many factors, including environmental factors, can lead to immunologic system disturbances and vascular changes. Endothelial alterations may lead to a cascade of stimulatory changes that involve many cells, including fibroblasts, T lymphocytes, macrophages and mast cells. In turn, the activated cells secrete a variety of substances, including cytokines and their soluble receptors and enzymes and their inhibitors. These substances lead to changes in the extracellular matrix compounds, including fibronectin, proteoglycans and collagen types I, III, V, and VII. Increased collagen deposition in tissues is a characteristic feature of systemic sclerosis (*Sakkas, 2005*).

Dermatomyositis (DM) is an idiopathic inflammatory myopathy with characteristic cutaneous findings, but may also affect the joints, the esophagus, the lungs and less commonly the heart (*Callen and Wortmann, 2006*).

The cutaneous disease may precede the development of the myopathy in patients with dermatomyositis. In addition, the existence of another subset of patients with dermatomyositis that affects only the skin (amyopathic dermatomyositis) has been recognized. Finally, another subset of patients with dermatomyositis are those with controlled myopathy who continue to have severe and sometimes debilitating skin disease (postmyopathic dermato-myositis) (*Bohan and Peter, 1975*).

The most common symptoms and signs of dermatomyositis include: a violet colored or dusky red rash which can be itchy or painful, most commonly on face, eyelids, knuckles, elbows, knees, chest and back “often it is the first sign of dermatomyositis” and progressive muscle weakness involves the muscles of both right and left sides closest to the trunk, such as those in hips, thighs, shoulders, upper arms and neck (*Dalakas and Hohlfeld, 2003*).

The cause of dermatomyositis is unknown. However, genetic, immunologic, infectious and environmental factors have been implicated (*Werth et al., 2002*).

Vascular endothelial growth factor (VEGF) is a sub-family of growth factors (the platelet-derived growth factor family of cysteine-knot growth factors) that are important signaling proteins involved in both vasculogenesis and angiogenesis (*Senger et al., 1983*).

It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate such as in hypoxic conditions. VEGF's normal function is to create new blood vessels during embryonic development, new blood vessels after injury of muscle following exercise and new vessels (collateral circulation) to bypass blocked vessels (*Palmer et al., 2014*).

When VEGF is over expressed, it can contribute to disease. Solid cancers cannot grow beyond a limited size without an adequate blood supply. However, cancers that can express VEGF are able to grow and metastasize. Moreover, Overexpression of VEGF can cause vascular disease in the retina of the eye and other parts of the body. Drugs such as aflibercept, bevacizumab and ranibizumab can inhibit VEGF and control or slow those diseases (*Harmey, 2004*).

Furthermore, VEGF is dysregulated in patients with connective tissue diseases (CTDs) such as scleroderma, systemic lupus erythematosus (SLE), rheumatoid arthritis, polymyositis, dermatomyositis and inclusion body myositis (*Distler et al., 2011*).

Dermatoscopy (DE), also called dermoscopy, is a noninvasive technique that allows a rapid and magnified in vivo observation of the skin surface with the visualization of morphologic features invisible to the naked eye. It is performed using manual devices without computer assistance, which generally allows x10 magnifications. Videodermatoscopy (VD) represents the evolution of DE and is performed by a video camera

equipped with optic fibers and lenses that currently allow magnifications ranging from x10 to x1000; the images obtained are visualized on a monitor and stored using a specific software on a personal computer to identify and compare changes over time (*Micali et al., 2009*).

Both DE and VD have been demonstrated to have further applications in dermatology apart from their use in the differential diagnosis of pigmented skin lesions, including some inflammatory diseases, cutaneous parasitoses, hair and nail abnormalities and a large variety of other dermatological conditions. In several disorders, they may be useful in differential diagnosis, prognostic evaluation and in evaluating the response to treatment (*Micali et al., 2009*).

The evaluation of the skin microvasculature is important in the evaluation of connective tissue diseases. In patients affected by SSc, the most typical nailfold capillary pattern of microangiopathy, the so-called scleroderma pattern (SP), is commonly observed (*Caramaschi et al., 2007*).

Three distinct nailfold capillary patterns of microangiopathy have been described in SSc patients: “early,” “active,” and “late,” which do not normally coexist at the same time. “Early” SP is characterized by irregularly enlarged capillaries, a few giant capillaries and hemorrhages; capillary architecture is almost regular without significant loss of capillaries. In the “active” SP pattern, frequent giant capillaries and hemorrhages may be

observed with mild loss of capillaries and capillary architecture disorganization. Severe loss of capillaries with a few giant capillaries, avascular areas, capillary architecture disorganization, and ramified capillaries are typical abnormalities of “late” SP. SSc patients with “late” capillary pattern show an increased risk for active disease and moderate/severe skin or visceral involvement, compared with patients with early and active patterns. The capillary features observed in dermatomyositis and in undifferentiated connective tissue disease are generally reported as being of the “scleroderma-like pattern” (*Hoert et al., 2012*).